BRK.A vs. LLY: Berkshire Hathaway vs. Eli Lilly Stock Comparison
How do Berkshire Hathaway (BRK.A) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Berkshire Hathaway (BRK.A) is classified in the Financials sector (Financial Services), whereas Eli Lilly (LLY) belongs to Health Care (Pharmaceuticals, Biotechnology & Life Sciences) — their GICS classifications point to very different parts of the market.
| Profile Item | BRK.A | LLY |
|---|---|---|
| Name | Berkshire Hathaway Inc. | Eli Lilly and Company |
| Country/Region | United States | United States |
| GICS Sector | Financials | Health Care |
| GICS Industry Group | Financial Services | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Financial Services | Pharmaceuticals |
| GICS Sub-Industry | Multi-Sector Holdings | Pharmaceuticals |
| Market Capitalization | 1,056.00 billion USD | 982.77 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | March 17, 1980 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Performance
Cumulative Growth
Trailing Returns
Performance at a Glance
| Metric | BRK.A | LLY |
|---|---|---|
| Total Return (1Y) | 0.60% | 45.51% |
Risk
Drawdown
Eli Lilly (LLY) trades around 3.17M shares per day on average, while Berkshire Hathaway (BRK.A) sees only 198 — a volume gap that can matter for position sizing, exit liquidity, and order execution.
Risk at a Glance
| Metric | BRK.A | LLY |
|---|---|---|
| Volatility (1Y, Annualized) | 13.98% | 37.97% |
| Beta (5Y) | 0.61 | 0.52 |
| Avg. Volume (3M) | 198 | 3.17M |
Profitability
ROE (TTM)
Eli Lilly (LLY) at 107.46% clears its industry range for ROE, a sharper capital-efficiency signal than Berkshire Hathaway (BRK.A) at 10.50%, which is closer to a typical peer reading.
BRK.A
Financial Services industry group
10.50%
- Max
- 42.17%
- Q3
- 21.57%
- Median
- 12.32%
- BRK.A
- 10.50%
- Q1
- 5.04%
- Min
- -17.69%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.46%
- LLY
- 107.46%
- Max
- 94.73%
- Q3
- 2.87%
- Median
- -31.21%
- Q1
- -61.22%
- Min
- -157.07%
Net Margin (TTM)
Eli Lilly (LLY) at 34.99% converts revenue to bottom-line profit above its industry’s benchmark range, while Berkshire Hathaway (BRK.A) at 19.31% keeps roughly the typical share for its industry.
BRK.A
Financial Services industry group
19.31%
- Max
- 66.55%
- Q3
- 30.45%
- BRK.A
- 19.31%
- Median
- 16.66%
- Q1
- 4.52%
- Min
- -26.88%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.99%
- LLY
- 34.99%
- Max
- 12.76%
- Q3
- 3.90%
- Median
- 0.00%
- Q1
- -2.01%
- Min
- -9.05%
Operating Margin (TTM)
Eli Lilly (LLY) at 49.39% operates in the top operating margin quartile, ahead of Berkshire Hathaway (BRK.A) at 14.35%, which runs around its industry’s norm.
BRK.A
Financial Services industry group
14.35%
- Max
- 95.95%
- Q3
- 48.40%
- Median
- 26.61%
- BRK.A
- 14.35%
- Q1
- 12.07%
- Min
- -36.26%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
49.39%
- Max
- 100.30%
- LLY
- 49.39%
- Q3
- 5.21%
- Median
- 0.00%
- Q1
- -122.23%
- Min
- -309.54%
Profitability at a Glance
| Metric | BRK.A | LLY |
|---|---|---|
| ROE (TTM) | 10.50% | 107.46% |
| ROA (TTM) | 5.39% | 20.74% |
| Net Margin (TTM) | 19.31% | 34.99% |
| Operating Margin (TTM) | 14.35% | 49.39% |
| Gross Margin (TTM) | -- | 82.83% |
Growth
Revenue Growth
Revenue Growth at a Glance
| Metric | BRK.A | LLY |
|---|---|---|
| Revenue Growth (YoY) | -3.23% | 44.70% |
| Revenue Growth (3Y CAGR) | 20.59% | 31.69% |
EPS Growth
EPS Growth at a Glance
| Metric | BRK.A | LLY |
|---|---|---|
| EPS Growth (YoY) | -24.78% | 95.99% |
| EPS Growth (3Y CAGR) | -- | 51.71% |
Financial Strength
Current Ratio (MRQ)
Eli Lilly (LLY) shows current ratio of 1.50; Berkshire Hathaway (BRK.A) doesn’t get one — Financial Services balance sheets aren’t split into current and non-current buckets, so short-term liquidity there is judged through regulatory measures instead.
BRK.A
Financial Services industry group
--
- BRK.A
- --
- Max
- --
- Q3
- --
- Median
- --
- Q1
- --
- Min
- --
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.50
- Max
- 24.76
- Q3
- 11.89
- Median
- 5.63
- Q1
- 2.69
- LLY
- 1.50
- Min
- 0.23
Debt / Equity (MRQ)
Eli Lilly (LLY) shows debt-to-equity ratio of 1.39; for Berkshire Hathaway (BRK.A) the ratio is set aside — in Financial Services, balance-sheet leverage is part of the business model itself, so capital-adequacy measures do the job this ratio does elsewhere.
BRK.A
Financial Services industry group
--
- BRK.A
- --
- Max
- --
- Q3
- --
- Median
- --
- Q1
- --
- Min
- --
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 1.60
- LLY
- 1.39
- Q3
- 0.68
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength at a Glance
| Metric | BRK.A | LLY |
|---|---|---|
| Current Ratio (MRQ) | -- | 1.50 |
| Debt / Equity (MRQ) | -- | 1.39 |
| Net Debt / EBITDA | -- | 1.05 |
Dividends
Dividend Yield (TTM)
Berkshire Hathaway (BRK.A) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.57%, ranking against industry peers normally.
BRK.A
Financial Services industry group
0.00%
- Max
- 9.57%
- Q3
- 3.98%
- BRK.A
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.57%
- LLY
- 0.57%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Berkshire Hathaway (BRK.A) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 22.13%, ranking against industry peers normally.
BRK.A
Financial Services industry group
0.00%
- Max
- 248.04%
- Q3
- 99.70%
- Median
- 25.37%
- BRK.A
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.13%
- LLY
- 22.13%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividends at a Glance
| Metric | BRK.A | LLY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.57% |
| Dividend Payout Ratio (TTM) | 0.00% | 22.13% |
Valuation
P/E Ratio (TTM)
Both Berkshire Hathaway (BRK.A) at 14.58 and Eli Lilly (LLY) at 39.22 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
BRK.A
Financial Services industry group
14.58
- Max
- 45.29
- Q3
- 25.35
- BRK.A
- 14.58
- Median
- 14.55
- Q1
- 9.01
- Min
- 0.62
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.22
- Max
- 79.44
- Q3
- 45.64
- LLY
- 39.22
- Median
- 24.21
- Q1
- 14.95
- Min
- 1.85
P/S Ratio (TTM)
On P/S ratio, both Berkshire Hathaway (BRK.A) at 2.81 and Eli Lilly (LLY) at 13.60 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BRK.A
Financial Services industry group
2.81
- Max
- 10.00
- Q3
- 4.88
- Median
- 2.89
- BRK.A
- 2.81
- Q1
- 1.44
- Min
- -1.20
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.60
- Max
- 54.89
- Q3
- 25.22
- LLY
- 13.60
- Median
- 7.22
- Q1
- 3.33
- Min
- 0.01
P/B Ratio (MRQ)
Berkshire Hathaway (BRK.A) at 1.45 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 31.56 prices above its benchmark range — LLY looks rich relative to book.
BRK.A
Financial Services industry group
1.45
- Max
- 7.19
- Q3
- 3.53
- Median
- 1.66
- BRK.A
- 1.45
- Q1
- 0.90
- Min
- 0.00
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.56
- LLY
- 31.56
- Max
- 14.41
- Q3
- 6.82
- Median
- 3.67
- Q1
- 1.70
- Min
- -5.92
Valuation at a Glance
| Metric | BRK.A | LLY |
|---|---|---|
| P/E Ratio (TTM) | 14.58 | 39.22 |
| P/S Ratio (TTM) | 2.81 | 13.60 |
| P/B Ratio (MRQ) | 1.45 | 31.56 |
| Free Cash Flow Yield (TTM) | -- | 0.93% |